Phase II Study of Low Dose Peginterferon Alfa-2b in Patients with Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor [ECOG 2602]
Principal Investigator:
Elyse Schneiderman, M.D.
Adventist Hinsdale Hospital
(630) 654-1790
Contact: Jan Wilson, R.N.
A Phase III Randomized Study of Four Weeks High Dose Interferon alfa-2B in Stage T3-T4 or N1 (microscopic) Melanoma [ECOG 1697]
Principal Investigator:
Elyse Schneiderman, M.D.
Adventist Hinsdale Hospital
(630) 654-1790
Contact: Jan Wilson, R.N.